arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Ultragenyx Pharmaceutical Inc.

RARE
$25.91 ▲ +0.07 (+0.25%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
15 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
18
Health
Poor
Bearish
auto_awesome

Analytical Summary

Ultragenyx Pharmaceutical Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $2.6B
Dividend Yield
Revenue Growth 20.2%
Op. Margin -79.5%
ROIC 673.4%
FCF / Share $-4.79
Trailing P/E
Price / Book
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

15-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$673.00M
↑ +20.2%
Net Income Profit after all expenses
$-575.00M
↓ -1.1%
Operating Margin Operating profit as % of sales
-79.5%
↑ +16.9% 3th
FCF / Share Free cash flow per share
$-4.79
↓ -2.9%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
3
Cash Quality
55

Dividend History

Dividend / share · sourced from SEC filings
$0.00 Latest / share

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 15 years · 55 quarters